Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN – Get Rating) was the recipient of a large decline in short interest in May. As of May 15th, there was short interest totalling 496,400 shares, a decline of 46.1% from the April 30th total of 921,700 shares. Approximately 2.8% of the company’s stock are short sold. Based on an average trading volume of 1,470,000 shares, the short-interest ratio is currently 0.3 days.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on SONN shares. Chardan Capital reduced their price objective on Sonnet BioTherapeutics from $17.00 to $14.00 in a research note on Wednesday, May 10th. EF Hutton Acquisition Co. I restated a “buy” rating and set a $6.70 price target on shares of Sonnet BioTherapeutics in a research report on Wednesday, April 19th.
Insider Buying and Selling
In related news, CEO Pankaj Mohan acquired 371,600 shares of Sonnet BioTherapeutics stock in a transaction on Monday, May 15th. The shares were purchased at an average cost of $0.22 per share, for a total transaction of $81,752.00. Following the purchase, the chief executive officer now directly owns 553,331 shares of the company’s stock, valued at approximately $121,732.82. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.00% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Sonnet BioTherapeutics
Sonnet BioTherapeutics Stock Up 38.4 %
NASDAQ:SONN opened at $0.40 on Friday. Sonnet BioTherapeutics has a 52-week low of $0.21 and a 52-week high of $4.56. The business’s 50-day moving average price is $0.33 and its 200 day moving average price is $0.80.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
- Get a free copy of the StockNews.com research report on Sonnet BioTherapeutics (SONN)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.